Login to Your Account



Clinic Roundup


Monday, April 18, 2011
Halozyme Therapeutics Inc., of San Diego, said results in a Type I diabetes study of patients who receive their insulin treatment via pump demonstrated that Aspart-PH20, a formulation of the company's rHuPH20 (recombinant human hyaluronidase) with the active ingredient in NovoLog (aspart, Novo Nordisk A/S), accelerated insulin absorption and shortened its duration of action. Data were presented at the American Association of Clinical Endocrinologists meeting in San Diego.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription